Trial reportAmerican journal of clinical oncology2012
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Trial report in American journal of clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.The oncologist · 2014Trial
- Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Review
- Role of heterocycles in inhibition of VEGFR-2 - a recent update (2019-2022).RSC medicinal chemistry · 2024Review
- Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3Drug design, development and therapy · 2024Article
- Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights.International journal of molecular sciences · 2021Review
- Novel molecular targets in hepatocellular carcinoma.World journal of clinical oncology · 2020Review
- Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies.Digestive diseases and sciences · 2019Review
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma.Clinical and molecular hepatology · 2017Review
- Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.Oncotarget · 2017Review
- Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Clinical and translational gastroenterology · 2017Article
- Systemic therapy for advanced hepatocellular carcinoma: an update.Journal of gastrointestinal oncology · 2017Review
- Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.Frontiers in pharmacology · 2016Review
- Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Diseases (Basel, Switzerland) · 2015Review
- Hypertension in cancer patients treated with anti-angiogenic based regimens.Cardio-oncology (London, England) · 2015Review
- Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.World journal of hepatology · 2015Review
- Targeting the tumor stroma in hepatocellular carcinoma.World journal of hepatology · 2015Review
- Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.Investigational new drugs · 2014Article
- Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.World journal of gastroenterology · 2014Review
- Systemic therapy of hepatocellular carcinoma: current status and future perspectives.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesVascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of vascular endothelial growth factor signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC.
methodsTwenty-eight patients with unresectable or metastatic HCC were enrolled in this study. Patients received 45 mg of cediranib orally, once daily, for 28-day cycles. The primary objective of this phase II study was to assess 6-month survival. Secondary objectives were to assess tumor response, time to progression, and toxicity.
resultsAll 28 patients were evaluable for efficacy outcomes. Twelve patients (42.9%) survived 6 months, 15 (53.6%) died within 6 months, and 1 (3.6%) was lost to follow-up before 6 months. The median overall survival was 5.8 months (95% confidence interval, 3.4-7.3 mo). No patients experienced confirmed response. The median time to progression was 2.8 months (95% confidence interval, 2.3-4.4 mo). Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%).
conclusionsOwing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.